Novartis AG Stock News

This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.

Novartis on Wednesday had to correct comments made by Chairman Joerg Reinhardt to a Swiss newspaper, because his portrayal of conduct that led to a $678 million U.S. settlement over kickbacks last yea

Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.

Novartis AG (NYSE: NVS) says that its Phase 3 VISION study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patien

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a P

Holding Edgewell Personal Care has been a painful experience for a number of years, but this might be coming to an end.

The stock market has some major movers as noon rolls around on Friday and InvestorPlace is looking at what stocks are up today. The post Midday Market Update: What Stocks Are Up Today?

With the trading day more than halfway over, the broad markets were pushing higher yet again.

Molecular Partners AG (OTCMKTS: MLLCF) and its collaborator Novartis AG (NYSE: NVS) have announced initial results from the ongoing Phase 1 study of its COVID-19 antiviral treatment, ensovibep (

Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.

Swiss Pharma giant Novartis AG (NYSE: NVS) has agreed to help CureVac BV (NASDAQ: CVAC) produce its experimental COVID-19 vaccine, known as CVnCoV. Novartis plans to manufacture the mRNA molecu

The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update

making Novartis an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of NVS entered into oversold territory, changing hands as low as $86.472 per share.

Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.

Novartis is currently trading at a 6.75% free cash flow yield. The FCF is higher than the net income due to the amortization of intangibles.